Human CCR4 Full Length Protein, Flag,His Tag (Detergent)
分子別名（Synonym）
CKR4, K5-5,CD194,CMKBR4,ChemR13,CC-CKR-4,HGCN:14099
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Human CCR4 Full Length Protein, Flag,His Tag (CC4-H52D3) is expressed from human 293 cells (HEK293). It contains AA Asn 2 - Leu 360 (Accession # P51679-1).
Predicted N-terminus: Asp
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries flag tag at the N-terminus and polyhistidine tag at the C-terminus.
The protein has a calculated MW of 60.3 kDa.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>80% as determined by SDS-PAGE.
制劑（Formulation）
This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumastance should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS,pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
運(yùn)輸（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存儲(chǔ)（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 3 months under sterile conditions.
背景（Background）
C-C趨化因子受體4型是以下CC趨化因子的受體：CCL2、CCL4、CCL5、CCL17、CCL22，屬于G蛋白偶聯(lián)受體家族。趨化因子是一組小多肽，結(jié)構(gòu)上相關(guān)的分子，調(diào)節(jié)各種類型白細(xì)胞的細(xì)胞運(yùn)輸。趨化因子在免疫系統(tǒng)的發(fā)育、穩(wěn)態(tài)和功能中也起著重要作用，它們對(duì)中樞神經(jīng)系統(tǒng)細(xì)胞以及參與血管生成或血管停滯的內(nèi)皮細(xì)胞都有影響。CCR4通常在皮膚T細(xì)胞淋巴瘤（CTCL）的白血病細(xì)胞上表達(dá)。Mogamulizumab是一種針對(duì)CCR4的人源化單克隆抗體，是CTCL的研究藥物。
關(guān)鍵字： CCR4;CCR4蛋白;CCR4重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。